April 2018-Global Life Science Business Partnering - News & Updates

Highlights for April 2018

  1. Glenmark enters licensing pact with Helsinn for its chemo-induced nausea drug.
  2. Chrys Capital-led consortium set to buy 10% in Mankind Pharma for $350M.
  3. Procter & Gamble (P&G), to acquire nearly 52% stake in drug firm Merck India
  4. Alexion inks $855M takeover of Wilson Therapeutics.
  5. Novo Nordisk moves into sickle cell with $400M EpiDestiny deal.
  6. Orion to sell its diagnostic unit to private equity group Axcel Management for around $200M upfront.
  7. Boston Scientific snaps up nVision Medical in deal worth $275M.
  8. Pernix and company inks $75M deal with Orexigen Therapeutics.
  9. Agilent Technologies buys DNA sequencing firm Lasergen for $105M.
  10. C4X Discovery signs licensing agreement with Indivior for addiction program worth up to $294M.
  11. Lilly and Sigilon Therapeutics Announce Strategic Collaboration to Develop Encapsulated Cell Therapies for the Treatment of Type 1 Diabetes, Sigilon receives $63M upfront.
  12. Compugen inks I-O deal worth over $210M with AZ unit MedImmune.
  13. United Therapeutics pens $216M deal to buy SteadyMed, neutralizing pump-based threat to PAH franchise.

Updates at Aagami:

  1. Aagami is all set for a strategic business trip with Client to New Jersey, New York and Philadelphia May 14-18.
  2. BIO 2018 - Calendar opens up for meetings. Please send requests via partnering system or by email to godwyn@aagami.com.
  3. New Client Win: US based US$700M company with revolutionary. Non-toxic, biodegradable product line. Aagami will support their Partnering needs across Asia including the Middle East.
×
Twitter